115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826
    Meeting Abstract

    Rutherford, S. C.; Li, H.; Herrera, A. F.; Leblanc, M.; Ahmed, S.; Davison, K. L.; Casulo, C.; Bartlett, N. L.; Tuscano, J. M.; Hess, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • (131)I-apamistamab effectively achieved durable responses in patients with R/R AML irrespective of the presence of multiple high-risk factors
    Meeting Abstract

    Seropian, S.; Foran, J. M.; Gyurkocza, B.; Nath, R.; Choe, H.; Litzow, M. R.; Koshy, N.; Stiff, P. J.; Tomlinson, B. K.; Abhyankar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: Results of the BMT CTN 1801 study
    Meeting Abstract

    Kean, L.; Siegel, S. J.; Schmalz, J. T.; Bien, S. A.; Scheffey, D.; Sanders, C.; Robins, H.; Applegate, K.; Bar, M.; Chhabra, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes of BMT CTN 1703: A randomized phase III study for GVHD prophylaxis - A quality of life evaluation
    Meeting Abstract

    Holtan, S. G.; Martens, M. J.; Al Malki, M. M.; Efebera, Y.; Kitko, C. L.; Reshef, R.; Rezvani, A. R.; Shaffer, B. C.; Solh, M. M.; Yao, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Allogeneic stem cell transplant and CD30 directed CART cell therapies are associated with improved survival in classical Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: Real world analysis from 14 US academic centers
    Meeting Abstract

    Voorhees, T.; Grover, N. S.; McLaughlin, E.; Florindez, J. A.; Moyo, T. K.; Reves, H.; Sumransub, N.; Deshpande, S.; Rose, A.; Duarte, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter study of mantle cell lymphoma outcomes following first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
    Meeting Abstract

    Wang, Y.; Larson, M. C.; Hwang, S. R.; Kumar, A.; Joseph, A.; Hill, B. T.; Brooks, T. R.; Bond, D. A.; Maddocks, K. J.; Danilov, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predictors of cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma and their impact on survival
    Meeting Abstract

    Shouval, R.; Strouse, C.; Kim, S.; Oloyede, T.; Ahmed, S.; Awan, F. T.; Bachanova, V.; Badar, T.; Barba, P.; Beitinjaneh, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • ALLO-647 for lymphodepletion in the allogeneic CAR T setting: Safety experience with ALLO-501/501A in patients (pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas
    Meeting Abstract

    Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; Eradat, H. A.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world evidence in the United States (US) of the impact of bridging therapy prior to axicabtagene ciloleucel (axi-cel) for the treatment of relapsed or refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Cook, M. R.; Shouval, R.; Perales, M. A.; Bezerra, E.; Niu, A.; Dahiya, S.; Nastoupil, L. J.; Jacobson, C. A.; Budde, L. E.; Olson, A. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial
    Meeting Abstract

    Jacobsen, E.; Maruyama, D.; Porcu, P.; Tobinai, K.; Allen, P. B.; Ishitsuka, K.; Tsukasaki, K.; Kusumoto, S.; Foss, F. M.; Yamauchi, N.; more...
    Blood (2023)

    Fulltext@MSK | Save